Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

DARA BioSciences Inc (NASDAQ:DARA)

0.8552
Delayed Data
As of Sep 01
 -0.0178 / -2.04%
Today’s Change
0.67
Today|||52-Week Range
1.27
-2.82%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$17.2M

Company Description

DARA BioSciences, Inc. is a pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. The company's product portfolio includes Soltamox, Gelclair, Bionect and KRN5500. Soltamox offers a choice to patients who prefer or need a liquid form of tamoxifen. Gelclair is an alcohol-free bioadherent oral rinse gel for rapid and effective relief of pain associated with oral mucositis caused by chemotherapy and radiation treatment. The company markets Bionect, a topical treatment for skin irritation and burns associated with radiation therapy, in U.S. oncology/radiology markets. DARA BioSciences was founded by Steven Gorlin on June 22, 2002 and is headquartered in Raleigh, NC.

Contact Information

DARA BioSciences, Inc.
8601 Six Forks Road
Raleigh North Carolina 27615
P:(919) 872-5578
Investor Relations:
(908) 938-1475

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

David J. DrutzExecutive Chairman & Chief Medical Officer
Christopher G. ClementPresident, Chief Executive Officer & Director
David L. TousleyChief Financial Officer & Executive Vice President
Mary Kay DelmedicoVice President-Scientific & Regulatory Affairs
John C. PetrolinoChief Compliance Officer & General Counsel